Clinical Trial

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2021-06-11; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2023-10-03
Trial Details
NCT Number NCT04929236
Lead Sponsor Octapharma
Conditions Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 30 participants
Start Date 2023-10-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-05